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Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent
malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in
use, techniques, and survival in a population-based cohort of 68,404 patients who underwent ﬁrst auto-HCT
in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood
and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest
during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs
done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in
1994-1995 to 5459 annually in 2004-2005, reﬂecting increased use for multiple myeloma, non-Hodgkin
lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53 years,
there has been a signiﬁcant improvement in overall survival (OS) from 1994 to 2005 in patients with
chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day þ100 OS, from 85% to 96%; 1-year OS, from
68% to 80%; P < .001) and chemotherapy-sensitive multiple myeloma (day þ100 OS, from 96% to 98%; 1-year
OS, from 83% to 92%; P < .001). This improvement in OS was most pronounced in middle-aged (>40 years)
and older (>60 years) individuals.
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13.04.027tumors. Over the last 2 decades, the practice of auto-HCT has
evolved to include a new source of hematopoietic cells
(peripheral blood) [1], new diseases/indications for which it
has demonstrated efﬁcacy and improved survival [2,3], aswell
as elimination of use for some indications, such as breast and
ovarian cancer, for which it has not been shown to be superior
to chemotherapy [4-6]. Improvements in supportive care
include new antimicrobial agents, improved radiographic
testing, and enhanced care deriving from increased experi-
ence with auto-HCT. Simultaneously, there have been major
changes in cancer treatment, with the development of
monoclonal antibodies (eg, rituximab, alemtuzumab),
immunomodulatory drugs (eg, thalidomide, lenalidomide),
small-molecule inhibitors (eg, bortezomib, sirolimus, temsir-
olimus, everolimus), hypomethylating agents (eg, azacitidine,Transplantation.
P.L. McCarthy Jr. et al. / Biol Blood Marrow Transplant 19 (2013) 1116e1123 1117decitabine), and other novel therapies. The introduction of
these novel agents may have affected referral patterns and
indications for auto-HCT [7-9]. In addition, nonmedical factors
have affected the application of auto-HCT, for example, vari-
able insurance coverage for tandem auto-HCT for multiple
myeloma [10-13].
The existence of the Center for International Blood and
Marrow Transplant Research (CIBMTR), a worldwide registry
and observational database of HCT, makes it possible to study
whether, and if so how, the use of auto-HCT to treat cancer
and other disorders has changed over time, as well as to
evaluate historical trends in overall survival (OS) after auto-
HCT. In the present study, we evaluated the auto-HCT
recipient population and analyzed OS in disease and age
subgroups for the 12-year period 1994-2005.
METHODS
About the CIBMTR
The CIBMTR was established in 2004 as a research afﬁliation of the
International Bone Marrow Transplant Registry (IBMTR), the Autologous
Blood and Marrow Transplant Registry (ABMTR), and the National Marrow
Donor Program (NMDP), comprising a voluntary working group of more
than 450 transplantation centers worldwide that contribute detailed data
on consecutive allogeneic HCTs (allo-HCTs) and auto-HCTs to a Statistical
Center at the Medical College of Wisconsin in Milwaukee and the NMDP
Coordinating Center inMinneapolis. The IBMTR has been collecting allo-HCT
data from centers worldwide since 1972, and the ABMTR has collected auto-
HCT data from centers in North and South America since 1991. Participating
centers are required to report all HCTs consecutively; compliance is moni-
tored by onsite audits. Patients are followed longitudinally. Computerized
checks for discrepancies, physicians’ review of submitted data, and onsite
audits of participating centers ensure data quality. Observational studies
conducted by the CIBMTR are performed under guidance of the Institutional
Review Boards of the Medical College ofWisconsin and the NMDP and are in
compliance with all applicable federal regulations pertaining to the pro-
tection of human research participants.
Data Collection and Reporting
The CIBMTR collects data at 2 levels: Transplantation Essential Data (TED)
and Comprehensive Report Form (CRF) data. TED data include disease type,
age, sex, pretransplantation disease stage and chemotherapy responsiveness
date of diagnosis, graft type (bonemarroweand/or blood-derived stem cells),
high-dose conditioning regimen, posttransplantation diseaseprogression and
survival, development of new malignancy, and cause of death. All CIBMTR
teams contribute TED data. More detailed disease and pretransplantation and
posttransplantation clinical data are collected from a subset of registered
patients selected for CRF data by a weighted randomization scheme. TED and
CRF data are collected pretransplantation, 100 days and 6 months post-
transplantation, and annually thereafter until death. The causes of death
(whether due to disease, treatment-related mortality, or other causes) were
not available for all patients, only for the subset of registeredpatients; thus,OS
is reported instead of cause-speciﬁc deaths.
Study Population
To reﬂect the broadest representation of HCT use for this study, TED-
level CIBMTR data were used. The study selection criteria were receipt of
ﬁrst auto-HCT at a US or Canadian center between 1994 and 2005. The ﬁnal
study population comprised 68,404 recipients of ﬁrst auto-HCT.
A total of 206 transplantation centers contributed data to the CIBMTR
during the study period. Eighty centers (39%) reported at least 1 auto-HCT to
the CIBMTR during each of the 12 years in the study period (1994-2005
inclusive); 51 (25%) provided data for less than one-half of the study period.
Statistical Analysis
The division of the 12-year study period into 6 cohorts, each consisting
of 2-year time periods, was determined to be the best delineation of the
study period to describe trends over time. Descriptive statistics, including
proportion, median, and range, were calculated. There were no tests of
statistical signiﬁcance for volume data. Estimates of OS with 95% conﬁdence
intervals (CIs) were calculated at day þ100, which represents early
transplantation-related mortality (TRM), and at 1 year, which represents
disease-related mortality and later TRM. Statistical signiﬁcance was
measured using Ptrend values over the 6 time cohorts to test whether the OS
estimates were stable (slope¼ 0), increasing (slope>0), or decreasing (slope
<0) over time. OS estimates were determined for a priori deﬁned diseaseand disease status subgroups and were not adjusted for any covariates
(eg, age, Karnofsky Performance Status [KPS] score). Disease status
subgroups with signiﬁcant trends in OS over time were stratiﬁed by age to
identify the pattern of OS trends by age. To reduce the type I error, P < .01
was considered to indicate statistical signiﬁcance.
Estimation of the Rate of Auto-HCT Over Time
The age-speciﬁc incidence of 6 major hematologic disorders (acute
lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin
lymphoma [HL], non-Hodgkin lymphoma [NHL], multiple myeloma [MM],
and myelodysplastic syndromes) was obtained from the National Cancer
Institute’s Surveillance, Epidemiology and End Results (SEER) database for
1994-2005 (http://seer.cancer.gov/). The age-speciﬁc intercensal population
estimates from 1994 to 2005 were obtained from the US Census Bureau
(http://www.census.gov). The number of new cases of each disease by age
group and year was estimated by applying the age-speciﬁc SEER incidence
to the US national population in that age group. Auto-HCTs performed for
these 6 major hematologic disorders were actual numbers reported to the
CIBMTR, which captured approximately 45%-70% of all auto-HCTs per-
formed at US transplantation centers during the period 1994-2005. Thus, an
inﬂation factor of 1.33-1.54 was applied to account for variances in the
proportion of all auto-HCTs performed in the United States that were re-
ported to the CIBMTR. The rate of auto-HCT for each disease was calculated
by dividing the number of auto-HCTs (after applying the inﬂation factor) by
the number of newly diagnosed cases, excluding incident cases and auto-




Characteristics of the auto-HCT recipients are summarized
in Table 1. The greatest number of auto-HCTs were performed
in the 4 years from 1996-1999 (n¼ 27,794), with a decrease in
volume in the subsequent 4-year period (n ¼ 19,135 in 2000-
2003). The number of transplantation centers with active
reporting in any 2-year period ranged from 197 to 241. The
median recipient age increased by almost 1 decade over the
study period (from 44 years in 1994-1995 to 53 years in 2004-
2005). Although the number of auto-HCT recipients aged
70 years has increased, these individuals still comprise only
5% of all auto-HCT recipients. In comparison, 60-year olds
constitute 25%, and 50-year olds constitute an additional 30%
of all auto-HCT recipients. Since 2000, one-half of all auto-
HCTs have been performed recipient aged 50 years. Collec-
tion of KPS data has improved over the entire study period,
from 60%missing data in 1994-1995 to only 15% missing data
in 2004-2005. Because of incomplete data on KPS for most of
the study period, assessing changes in this patient character-
istic over time is difﬁcult. Between 1997 and 1998, there was
an improvement in the completeness of data collected for
race. Since 1998, the proportion of auto-HCTs performed in
non-white racial/ethnic recipients has remained stable. The
number of auto-HCTs performed in Canada increased by>60%
between 1994-1995 and 2004-2005.
Disease Indications and High-Dose Regimens
Whereas the majority of auto-HCTs performed in 1994-
1995 were for breast cancer (42%) and NHL (24%), in 2004-
2005 MM (44%), NHL (29%), and HL (12%) were the most
common indications. The peak period for auto-HCT for breast
cancer was 1996-1997, with an annual average of 3074;
in 2004-2005, the annual average was only 61. In contrast,
in 1994-1995 a total of 678 auto-HCTs (annual average, 339)
were performed for MM, compared with a peak of 4773
(yearly average, 2386) in 2004-2005. In 1994-1995, the
majority of auto-HCTs for MM were performed in patients
with advanced disease, rather than those in ﬁrst complete
remission (CR1) or partial remission (PR) (50% versus 23%),
whereas in 2004-2005, the situation was reversed (21% for
Table 1
Characteristics of Patients from the United States and Canada Who Received and Registered an Auto-HCT to the CIBMTR, 1994-2005
Variable 1994-1995 1996-1997 1998-1999 2000-2001 2002-2003 2004-2005
Patient related
Number of patients 10,557 13,665 14,129 9686 9449 10,918
Number of centers 197 225 241 229 210 203
Age, yrs, median (range) 44 (<1-75) 46 (<1-76) 48 (<1-78) 50 (<1-78) 52 (<1-91) 53 (<1-81)
Age group, yrs, n (%)
<1-9 435 (4) 430 (3) 577 (4) 434 (4) 503 (5) 532 (5)
10-19 384 (4) 386 (3) 419 (3) 342 (4) 305 (3) 366 (3)
20-29 819 (8) 849 (6) 838 (6) 708 (7) 599 (6) 680 (6)
30-39 2129 (20) 2363 (17) 2060 (15) 1121 (12) 902 (10) 907 (8)
40-49 3453 (33) 4406 (32) 3945 (28) 2004 (21) 1689 (18) 1824 (17)
50-59 2622 (25) 3845 (28) 4438 (31) 2960 (31) 2869 (30) 3292 (30)
60-69 671 (6) 1317 (10) 1731 (12) 1902 (20) 2203 (23) 2766 (25)
70 22 (<1) 54 (<1) 111 (1) 203 (2) 377 (4) 548 (5)
Missing 22 (<1) 15 (<1) 10 (<1) 12 (<1) 2 (<1) 3 (<1)
Male sex, n (%) 3549 (34) 4352 (32) 4995 (35) 5306 (55) 5382 (57) 6463 (59)
Missing, n (%) 58 (1) 11 (<1) 56 (<1) 12 (<1) 26 (<1) 25 (<1)
Karnofsky/Lansky performance score, n (%)
80 4012 (38) 5171 (38) 4659 (33) 6426 (66) 7293 (77) 8631 (79)
<80 231 (2) 302 (2) 291 (2) 427 (4) 479 (5) 617 (6)
Missing 6314 (60) 8192 (60) 9179 (65) 2833 (29) 1677 (18) 1670 (15)
Race, n (%)
White 6297 (60) 8910 (65) 11,402 (81) 7731 (80) 7455 (79) 8653 (79)
African American 458 (4) 661 (5) 1056 (7) 830 (9) 912 (10) 1063 (10)
Asian/Paciﬁc Islander 110 (1) 159 (1) 225 (2) 181 (2) 150 (2) 186 (2)
Hispanic 259 (2) 332 (2) 538 (4) 330 (3) 281 (3) 228 (2)
Other 34 (<1) 46 (<1) 80 (1) 116 (1) 158 (2) 426 (4)
Missing 3399 (32) 3557 (26) 828 (6) 498 (5) 493 (5) 362 (3)
Country, n (%)
United States 9820 (93) 12674 (93) 12998 (92) 8560 (88) 8323 (88) 9717 (89)
Canada 737 (7) 991 (7) 1131 (8) 1126 (12) 1126 (12) 1201 (11)
Disease related
Disease, n (%)
MM 678 (6) 1360 (10) 2317 (16) 3091 (32) 3858 (41) 4773 (44)
NHL 2573 (24) 3060 (22) 3079 (22) 3140 (32) 2842 (30) 3164 (29)
HL 906 (9) 1007 (7) 1158 (8) 1098 (11) 1135 (12) 1302 (12)
Solid tumor (not breast cancer) 968 (9) 1263 (9) 1445 (10) 883 (9) 892 (9) 963 (9)
AML 639 (6) 499 (4) 575 (4) 442 (5) 472 (5) 506 (5)
Breast cancer 4401 (42) 6148 (45) 5199 (37) 815 (8) 125 (1) 61 (1)
ALL 133 (1) 79 (1) 75 (1) 40 (<1) 27 (<1) 43 (<1)
Chronic lymphocytic leukemia 28 (<1) 47 (<1) 80 (1) 61 (1) 27 (<1) 24 (<1)
Autoimmune diseases 0 12 (<1) 36 (<1) 49 (1) 28 (<1) 22 (<1)
Myelodysplastic syndrome/myeloproliferative
disorder
22 (<1) 22 (<1) 33 (<1) 24 (<1) 16 (<1) 13 (<1)
Other leukemias 63 (1) 52 (<1) 27 (<1) 15 (<1) 12 (<1) 11 (<1)
Chronic myelogenous leukemia 88 (1) 67 (<1) 80 (1) 17 (<1) 4 (<1) 5 (<1)
Other 42 (<1) 32 (<1) 18 (<1) 9 (<1) 11 (11) 31 (<1)
Missing 16 (<1) 17 (<1) 7 (<1) 2 (<1) 0 0
Disease status pretransplantation, n (%)
AML
CR1 336 (53) 262 (53) 313 (54) 276 (62) 329 (70) 338 (67)
CR2 or greater 148 (23) 108 (22) 139 (24) 95 (21) 100 (21) 126 (25)
Relapse/primary induction failure 91 (14) 63 (13) 68 (12) 31 (7) 23 (5) 22 (4)
Other/unknown/missing 64 (10) 66 (13) 55 (10) 40 (9) 20 (4) 20 (4)
ALL
CR1 46 (35) 30 (38) 29 (39) 23 (58) 18 (67) 28 (65)
CR2 or greater 63 (47) 28 (35) 23 (31) 10 (25) 7 (26) 10 (23)
Relapse/primary induction failure 17 (13) 12 (15) 14 (19) 6 (15) 1 (4) 1 (3)
Other/unknown/missing 7 (5) 9 (11) 9 (12) 1 (3) 1 (4) 4 (9)
NHL
CR2/ﬁrst chemosensitive relapse 895 (35) 1073 (35) 1050 (34) 1026 (33) 952 (34) 1118 (35)
CR1 238 (9) 241 (8) 363 (12) 409 (13) 509 (18) 636 (20)
CR3/second or greater chemosensitive
relapse
211 (8) 252 (8) 304 (10) 274 (9) 226 (8) 259 (8)
Other/unknown/missing 1229 (48) 1494 (49) 1362 (44) 1431 (46) 1155 (41) 1151 (36)
HL
CR2/ﬁrst chemosensitive relapse 348 (38) 387 (38) 468 (41) 440 (40) 477 (42) 578 (44)
CR1 21 (2) 21 (2) 47 (4) 50 (5) 47 (4) 81 (6)
CR3/second or greater chemosensitive
relapse
106 (12) 88 (9) 113 (10) 94 (9) 70 (6) 100 (8)
Other/unknown/missing 431 (48) 511 (51) 530 (46) 514 (47) 541 (48) 543 (42)
MM
CR1 or PR 153 (23) 366 (27) 667 (29) 1554 (50) 2407 (62) 3196 (67)
Other* 342 (50) 499 (37) 648 (28) 802 (26) 907 (24) 1009 (21)
Unknown/missing 183 (27) 495 (36) 1002 (43) 735 (24) 544 (14) 568 (12)
(continued on next page)
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Table 1
(continued)
Variable 1994-1995 1996-1997 1998-1999 2000-2001 2002-2003 2004-2005
Transplantation-related
Time from diagnosis to transplantation, median
(range)
14 (<1-563) 12 (<1-619) 11 (<1-850) 11 (<1-734) 10 (<1-411) 10 (<1-877)
Time from diagnosis to transplantation, n (%)
<12 mo 4472 (42) 6414 (47) 7049 (50) 4899 (51) 5133 (54) 6035 (55)
12-23 mo 2068 (20) 2391 (17) 2566 (18) 2024 (21) 1886 (20) 2271 (21)
24-35 mo 1105 (10) 1325 (10) 1262 (9) 891 (9) 731 (8) 883 (8)
36 mo 2351 (22) 2842 (21) 2658 (19) 1497 (15) 1379 (15) 1656 (15)
Missing 561 (5) 693 (5) 594 (4) 375 (4) 320 (3) 73 (1)
Graft source, n (%)y
Peripheral blood 6288 (60) 11,253 (82) 12,961 (92) 9104 (94) 9104 (96) 10,618 (97)
Bone marrow 2730 (26) 1470 (11) 657 (5) 296 (3) 193 (2) 208 (2)
Bone marrow and peripheral blood 1539 (15) 942 (7) 509 (4) 286 (3) 151 (2) 92 (1)
High-dose therapy regimens, n (%)
Melphalan 205 (2) 486 (4) 1089 (8) 1989 (21) 2833 (30) 3828 (35)
BEAM 73 (1) 141 (1) 537 (4) 805 (8) 1066 (11) 1222 (11)
Cyclophosphamide þ etoposide þ nitrosourea 1219 (12) 1469 (11) 1474 (10) 1100 (11) 826 (9) 944 (9)
Busulfan þ cyclophosphamide  other 1173 (11) 1162 (9) 1128 (8) 938 (10) 800 (8) 730 (7)
Cyclophosphamide  other 2471 (23) 2900 (21) 2356 (17) 847 (9) 485 (5) 404 (4)
Cyclophosphamide þ total body irradiation 
other
1135 (11) 1021 (7) 1015 (7) 647 (7) 370 (4) 321 (3)
Etoposide þ melphalan  other 165 (2) 142 (1) 154 (1) 99 (1) 116 (1) 260 (2)
BEAM þ monoclonal antibody  other 0 0 14 (<1) 43 (<1) 100 (1) 200 (2)
Busulfan þ etoposide  other 67 (1) 69 (1) 142 (1) 94 (1) 137 (1) 147 (1)
Carboplatin þ etoposide þ melphalan  other 104 (1) 166 (1) 240 (2) 95 (1) 204 (2) 134 (1)
Carboplatin þ thiotepa  other 146 (1) 147 (1) 146 (1) 116 (1) 147 (2) 94 (1)
Melphalan  other (no radiation) 34 (<1) 41 (<1) 193 (1) 151 (2) 102 (1) 89 (1)
Carboplatin þ etoposide 66 (1) 97 (1) 58 (<1) 53 (1) 69 (1) 88 (1)
Total body irradiation  other 234 (2) 540 (4) 732 (5) 357 (4) 78 (1) 78 (1)
Busulfan þ melphalan  other (no thiotepa) 36 (<1) 65 (<1) 46 (<1) 34 (<1) 42 (<1) 72 (1)
Busulfan þ melphalan þ thiotepa  other 41 (<1) 165 (1) 141 (1) 58 (1) 28 (<1) 70 (1)
Cyclophosphamide þ thiotepa þ carboplatin 1625 (15) 2793 (20) 2854 (20) 380 (4) 33 (<1) 21 (<1)
Carboplatin þ etoposide þ ifosfamide  other 164 (2) 109 (1) 77 (1) 27 (<1) 18 (<1) 5 (<1)
Other 1304 (12) 1374 (10) 1120 (8) 457 (5) 374 (4) 399 (4)
Missing 295 (3) 778 (6) 613 (4) 1396 (14) 1621 (17) 1812 (17)
Type of second transplantation, n (%)
One transplantation only 9741 (92) 12,609 (92) 12,980 (92) 8636 (89) 8230 (87) 9151 (84)
Two or more transplantations
First autologous, second allogeneic,
second planned
1 (<1) 4 (<1) 7 (<1) 24 (<1) 61 (1) 145 (1)
First autologous, second allogeneic,
second unplanned
193 (2) 282 (2) 380 (3) 429 (4) 505 (5) 485 (4)
First autologous, second autologous,
second planned
167 (2) 289 (2) 313 (2) 277 (3) 285 (3) 786 (7)
First autologous, second autologous,
second unplanned
455 (4) 479 (4) 447 (3) 317 (3) 364 (4) 345 (3)
Missing 0 2 (<1) 2 (<1) 3 (<1) 4 (<1) 6 (<1)
* Others includes minimal response, no response/stable disease, progression/relapse, and CR2 or greater.
y One autologous cord blood transplantation was performed in 2002-2003 in a 1-year-old with severe aplastic anemia.
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use of auto-HCT to treat patients with early-stage acute
leukemias (AML, ALL) and HL increased, with a rise in
the proportion of patients undergoing auto-HCT within
12 months after diagnosis from 42% in 1994-1995 to 55% in
2004-2005.
The high-dose regimens used for auto-HCT have changed
over time, in parallel with the changes in the diseases treated.
Application of cyclophosphamide þ thiotepa þ carboplatin
regimens, once commonly used to treat breast cancer,
declined froman annual peak of 1427 in 1998-1999 to a lowof
10 in 2004-2005. The use ofmelphalan to treatMM increased
from an annual low of 103 in 1994-1995 to a high of 1914 in
2004-2005. The use of carmustine þ etoposide þ cytosine
arabinoside þ melphalan (BEAM), most commonly to treat
lymphoma, increased from 37 annually in 1994-1995 to 611
annually in 2004-2005. The use of cyclophosphamide þ total
body irradiation regimens decreased over the study period,reﬂecting its decreased application in patients with NHL. The
use of other regimens declined from 652 annually in 1994-
1995 to 200 annually in 2004-2005, suggesting increased use
of standard regimens.
The use of planned tandem auto-HCT increased from 167
in 1994-1995 to 786 in 2004-2005, most likely reﬂecting the
increase in use of auto-HCT to treat MM. The frequency of
a second unplanned auto-HCT remained stable over the
study period. The numbers of planned and unplanned
second allo-HCT after a ﬁrst auto-HCT both increased over
time, to 145 and 485, respectively, in 2004-2005.
Use of Auto-HCT Over Time
The incidence rate of auto-HCT over time is summarized
in Table 2. The proportion of the US population aged
0-74 years increased by 10.6% between 1994 and 2005. For
NHL, the incidence rate of auto-HCT in 0- to 74-year old
individuals remained stable, and the incident cases increased
Table 2
Changes Over Time in the US Population, Incident Cases, and Proportion of Cases who Underwent Auto-HCT














Incidence rate per 100,000 persons 5.2 5.0 5.2 5.5 5.0 4.7
Number of new incident cases aged 0-74 yrs 12,879 12,683 13,682 14,608 13,532 13,131
Rate of auto-HCT aged 0-74 yrs per new incident cases, % 6.6 5.3 5.5 3.9 4.8 5.0
ALL
Incidence rate per 100,000 persons 2.9 3.0 3.0 3.0 3.1 3.3
Number of new incident cases aged 0-74 yrs 7706 7592 7926 8055 8404 9067
Rate of auto-HCT aged 0-74 yrs per new incident cases, % 2.6 1.5 1.3 0.7 0.4 0.6
Myelodysplastic syndrome/myeloproliferative disorder
Incidence rate per 100,000 persons * * * * 3.8 3.9
Number of new incident cases aged 0-74 yrs * * * * 10,226 10,764
Rate of auto-HCT aged 0-74 yrs per new incident cases, % * * * * 0.2 0.2
NHL
Incidence rate per 100,000 persons 29.5 28.4 27.9 28.0 28.7 29.4
Number of new incident cases aged 0-74 yrs 73,658 72,650 72,925 74,614 77,973 81,272
Rate of auto-HCT aged 0-74 yrs per new incident cases, % 4.9 5.9 5.6 5.3 4.6 4.5
HL
Incidence rate per 100,000 persons 5.1 5.2 5.3 5.1 5.2 5.3
Number of new incident cases aged 0-74 yrs 12,787 13,330 13,856 13,707 14,212 14,706
Rate of auto-HCT aged 0-74 yrs per new incident cases, % 9.4 10.0 10.8 10.1 10.0 10.3
MM
Incidence rate per 100,000 persons 7.4 7.4 7.5 7.7 7.7 8.0
Number of new incident cases aged 0-74 yrs 18,422 19,006 19,498 20,468 20,863 22,123
Rate of auto-HCT aged 0-74 yrs per new incident cases, % 5.1 9.8 15.6 18.3 22.6 25.1
* SEER did not initiate data collection for myelodysplastic syndrome/myeloproliferative disorder until 2001.
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ulation. The incidence rate of auto-HCT for NHL initially
increased by 20% (from 3.2% to 3.8%) from 1994-1995 to
1996-1997, then decreased in the 2002-2003 and 2004-2005
cohorts to close to the 1994-1995 baseline rate. For HL, the
incidence rate increased by 4% and the incident cases
increased by 15%, exceeding the increase in the US pop-
ulation, and the rate of auto-HCT for HL increased by 28%
(from 6.1% to 7.8%) during this time. For MM, the incidence
rate increased by 8% and the incident cases increased by 20%,
exceeding the rate of increase in the US population; however,
the rate of auto-HCT for MM increased by almost 5-fold
during this time, from 5.1% to 25.1%. For AML, the incidence
rate decreased by 10%, whereas the incident cases increased
by 2%, and the rate of auto-HCT for AML decreased by 12%
over the study period, from 4.3% to 3.8%. For ALL, the inci-
dence rate increased by 14% and the incident cases increased
by 18%; however, the rate of auto-HCT for ALL decreased by
71%, to 0.5%.OS
OS estimates at 100 days after auto-HCT were generally
high for all diseases examined and improved signiﬁcantly
over time for NHL in second complete remission (CR2) or ﬁrst
chemotherapy-sensitive relapse and MM in CR1 or PR1,
especially in patients aged >40 years (Table 3). Statistically
signiﬁcant improvements in 1-year OS after auto-HCT were
observed for NHL in CR2 or ﬁrst chemosensitive relapse and
for MM in CR1/PR1 at the time of auto-HCT. Although the
1-year OS improved over time, therewas a signiﬁcant decline
in OS between the day-100 and 1-year time points, especially
for patients with NHL in CR2/ﬁrst chemotherapy sensitive
relapse and those with chemotherapy-resistant lymphoma
and MM, likely reﬂecting relapse of the underlying malig-
nancy and suggesting the need for improved disease control
in these patients.DISCUSSION
Auto-HCTcontinues to be a treatment option primarily for
the management of hematologic disorders. The use of auto-
HCT remained more or less stable for AML, HL, and NHL
over our study period and mirrored the increased incidence
of these diseases in the general population. Its use for ALL
decreased, and its use for MM increased substantially. Auto-
HCT is still used for some less common nonhematologic
disorders, including neuroblastoma, central nervous system
tumors, and relapsed testicular cancer. The use of auto-HCT
for breast cancer treatment, for either adjuvant or meta-
static disease, has essentially stopped [5], likely owing to the
lack of evidence of the superiority of auto-HCT over lower-
dose therapy in several randomized trials. The decrease in
the number of centers reporting auto-HCTs to the CIBMTR
during our study period is directly related to the reduced use
of auto-HCT for breast cancer, given that several centers
performed auto-HCT only for breast cancer.
There has been limited growth in the use of auto-HCT for
autoimmune disorders, such as rheumatoid arthritis,
systemic lupus erythematosis, inﬂammatory bowel disease,
systemic sclerosis, and multiple sclerosis. This slow growth
may be related to the initial high morbidity and mortality
rates associated with auto-HCT, as well as to the availability
of new treatment agents, such as inﬂiximab and etanercept
for rheumatoid arthritis and inﬂammatory bowel disease
and IFNb-1a and b-1b, glatiramer acetate, natalizumab, and
ﬁngolimod for multiple sclerosis.
The story is different for patients with MM. In 1996, the
ﬁrst randomized trial demonstrated improved response
rates, event-free survival, and OS in patients with MM
undergoing auto-HCT compared with those receiving lower-
dose chemotherapy [2]. Our data demonstrate a 5-fold
increase in the total number of auto-HCTs for MM and
a 20-fold increase in the number of auto-HCTs as part of
initial therapy for patients in CR1 or PR since that time.
Randomized clinical trials of HCT versus novel therapy
Table 3
OS Estimates by Disease and Disease Status Subgroups, Stratiﬁed by age at Auto-HCT
Disease/Disease Status at HCT 1994-1995 1996-1997 1998-1999 2000-2001 2002-2003 2004-2005 Ptrend
NHL in CR2 or ﬁrst chemotherapy-sensitive relapse
All patients
Number of patients 890 1067 1041 1020 946 1116
OS (95% CI) at 100 days post-HCT 89 (87-91) 90 (88-92) 90 (88-92) 94 (92-95) 94 (92-95) 95 (94-97) <.001
OS (95% CI) at 1 yr post-HCT 68 (65-71) 69 (66-72) 72 (69-75) 77 (75-80) 78 (75-80) 80 (77-83) <.001
Age 20-39 yrs at time of HCT*
Number of patients 177 159 152 132 87 111
OS (95% CI) at 100 days post-HCT 96 (93-98) 91 (86-95) 97 (93-99) 96 (92-99) 94 (88-98) 97 (93-99) .3116
OS (95% CI) at 1 yr post-HCT 76 (70-82) 67 (59-74) 81 (74-87) 82 (75-89) 82 (73-90) 80 (71-88) .0365
Age 40-59 yrs at time of HCT
Number of patients 551 640 622 572 516 585
OS (95% CI) at 100 days post-HCT 88 (85-91) 91 (89-93) 90 (87-92) 94 (92-96) 95 (93-97) 95 (93-96) <.001
OS (95% CI) at 1 yr post-HCT 68 (64-72) 74 (70-77) 75 (71-78) 81 (77-84) 82 (78-85) 80 (76-84) <.001
Age 60 yrs at time of HCT
Number of patients 133 233 237 294 316 400
OS (95% CI) at 100 days post-HCT 85 (78-91) 86 (81-90) 86 (81-90) 91 (88-94) 93 (90-96) 96 (93-97) <.001
OS (95% CI) at 1 yr post-HCT 58 (49-66) 57 (51-64) 60 (53-67) 69 (63-74) 71 (65-76) 79 (75-83) <.001
NHL with no previous CR (induction failure),
All Patients
Number of patients 522 564 587 691 390 318
OS (95% CI) at 100 days post-HCT 86 (82-88) 88 (85-90) 87 (84-89) 89 (86-91) 88 (84-91) 90 (87-93) .2810
OS (95% CI) at 1 yr post-HCT 67 (63-71) 67 (63-71) 71 (67-74) 70 (66-73) 68 (63-73) 68 (62-73) .7946
HL in CR2 or ﬁrst chemotherapy-sensitive
relapse, All Patients
Number of patients 348 384 466 435 477 573
OS (95% CI) at 100 days post-HCT 95 (92-97) 95 (92-97) 96 (94-97) 97 (95-98) 96 (94-98) 97 (95-98) .4758
OS (95% CI) at 1 yr post-HCT 86 (82-89) 87 (84-91) 87 (83-90) 89 (85-92) 90 (87-93) 91 (88-93) .1985
HL with no previous CR (induction failure),
All Patients
Number of patients 125 144 185 214 180 186
OS (95% CI) at 100 days post-HCT 90 (85-95) 89 (84-94) 87 (82-92) 92 (88-95) 95 (92-98) 93 (89-96) .0667
OS (95% CI) at 1 yr post-HCT 76 (68-83) 73 (66-81) 69 (62-76) 77 (71-83) 78 (71-84) 79 (72-85) .3786
MM in CR1 or partial remission
All patients
Number of patients 276 541 718 1567 2423 3192
OS (95% CI) at 100 days post-HCT 96 (94-98) 96 (94-98) 96 (94-97) 97 (96-98) 98 (97-98) 98 (98-99) <.001
OS (95% CI) at 1 yr post-HCT 83 (79-88) 84 (81-87) 87 (85-90) 90 (89-92) 92 (91-93) 92 (91-93) <.001
Age 20-39 yrs at time of HCT
Number of patients 19 30 32 74 76 105
OS (95% CI) at 100 days post-HCT NE 97 (87-100) 100 100 99 (95-100) 98 (95-100) .8543
OS (95% CI) at 1 yr post-HCT NE 97 (87-100) 97 (87-100) 94 (87-98) 95 (88-99) 93 (87-97) .8998
Age 40-59 yrs at time of HCT
Number of patients 218 384 505 961 1391 1748
OS (95% CI) at 100 days post-HCT 97 (95-99) 97 (95-98) 96 (94-98) 97 (96-98) 98 (97-99) 99 (98-99) .0028
OS (95% CI) at 1 yr post-HCT 85 (80-89) 85 (81-89) 88 (85-91) 91 (89-93) 92 (90-93) 93 (91-94) <.001
Age 60 yrs at time of HCT
Number of patients 39 127 179 529 955 1337
OS (95% CI) at 100 days post-HCT 92 (82-98) 94 (90-98) 94 (90-97) 97 (95-98) 97 (96-98) 98 (97-99) .045
OS (95% CI) at 1 yr post-HCT 73 (57-86) 79 (71-85) 84 (78-90) 89 (86-91) 92 (90-93) 91 (90-93) <.001
MM in less than PR (minimum response, stable disease, resistant disease)
All patients
Number of patients 105 177 392 420 521 586
OS (95% CI) at 100 days post-HCT 92 (85-96) 94 (90-97) 96 (94-98) 96 (94-98) 97 (95-98) 95 (93-97) .3829
OS (95% CI) at 1 yr post-HCT 79 (70-87) 79 (73-85) 86 (82-89) 88 (84-91) 88 (85-91) 87 (84-90) .0857
Age 40-59 yrs at time of HCT
Number of patients 68 122 257 248 302 300
OS (95% CI) at 100 days post-HCT 92 (84-97) 94 (89-98) 96 (93-98) 95 (92-97) 97 (95-99) 98 (97-99) .0751
OS (95% CI) at 1 yr post-HCT 77 (65-87) 83 (75-89) 86 (81-90) 86 (81-90) 89 (85-93) 88 (83-91) .2728
Age 60 yrs at time of HCT
Number of patients 28 42 117 161 194 269
OS (95% CI) at 100 days post-HCT 88 (73-98) 90 (80-97) 97 (93-99) 97 (94-99) 95 (92-98) 91 (87-94) .0478
OS (95% CI) at 1 yr post-HCT 79 (60-93) 66 (51-79) 83 (74-89) 91 (85-95) 85 (80-90) 85 (80-90) .0272
NE indicates not evaluable; sample size, <25 patients in this subgroup.
* Subgroup analyses by age are presented for the highest-frequency groups.
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there is a more speciﬁc role for auto-HCT as part of upfront
therapy for MM. Conversely, auto-HCT may allow for less
exposure to prolonged therapy in patients with MM, owing
to a greater depth of response to auto-HCT compared with
novel agents, as preliminary reports have demonstrated [14].
Consolidation and maintenance strategies incorporating
novel agents (eg, bortezomib, lenalidomide) alongwith auto-HCT have been shown to improve survival, although more
research is still needed in this area, especially given the risks
(eg, secondary cancers with lenalidomide) and costs of these
approaches [15-17].
The use of auto-HCT for NHL and HL has increased despite
a decrease in the number of reporting autologous trans-
plantation centers. Rituximab received Food and Drug
Administration approval in 2006 for use as part of upfront
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[18]. The use of rituximab early in NHL treatment has
affected outcomes in patients who relapse, especially within
a year of completing up front therapy [8]. This patient pop-
ulation does poorly and might not go on to receive auto-HCT
owing to refractory disease. Considering that our study
period ended in 2005, how the use of rituximab outside of
clinical trials might affect the application of auto-HCT for
NHL or OS remains unknown. Nonetheless, our results show
no signiﬁcant improvement in OS over time in patients with
refractory NHL, demonstrating the need for newer agents
and approaches, such as maintenance therapy for high-risk
patients.
Nearly one-half of all auto-HCTs performed since 2000
have been in patients aged >50 years. This has several
implications. Given the higher incidence of cancer in older
individuals and the aging US and Canadian populations [19],
the use of auto-HCT for cancer treatment in the older (>50)
adult population is likely to expand. Moreover, in the present
study, patients aged>40with chemotherapy-responsiveMM
and NHL have experienced the greatest improvement in day-
100 and 1-year OS. The reasons for this improvement may be
multifactorial, reﬂecting improvements in patient selection,
identiﬁcation of candidates for auto-HCTearly in the course of
disease, better supportive care, and better deﬁnition of
optimal dose-intensive regimens. As an example, total body
irradiationecontaining regimens for lymphoma and mye-
loma, associated with greater toxicity without improved
outcomes, were more common in the earlier cohorts and
seldom used in the later cohorts of our study [3].
Many factors can inﬂuence a patient’s and physician’s
decision regarding the use of auto-HCT for therapy, including
age, disease and remission status, comorbidities, caregiver
support, insurance coverage, referring physician’s willing-
ness to refer the patient for HCT consultation, and timing of
patient referral. Although data were not available in this
study to identify factors that inﬂuence practice patterns,
inferences can be made based on clinical practice guidelines
and improved patient outcomes. Indeed, better outcomes
positively inﬂuence decision making regarding referral for
auto-HCT. Although signiﬁcant progress has been made in
early (day-100) survival rates, additional improvements are
still needed to decrease disease progression and relapse
posttransplantation to further improve long-term disease
control and cure rates.
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